Remove Antibody Remove Contract Manufacturing Remove Manufacturing
article thumbnail

High biologics demand spurs need for greater contract manufacturing

Pharmaceutical Technology

Biologics are costly to produce and sell, and the more recent modalities, such as cell and gene therapies, can be difficult to manufacture. These attributes make some biologic drugs, especially monoclonal antibodies more specific and targeted in their treatment.

article thumbnail

Chinese manufacturers’ transition to innovative pharma requires more investment

Pharmaceutical Technology

Despite China producing a significant proportion of the world’s API supply (mostly small molecule), it manufactures relatively few biosimilar and innovator drugs and no cell and gene therapies for the western markets of Europe and the US despite investments and an increasing number of startups to improve innovative manufacture.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Antibodies Contract Manufacturing Market Size and Market Analysis

BioTech 365

The global antibodies contract manufacturing market is expected to reach from USD 13.4 Rise in demand for the production of therapeutic antibodies … Continue reading → billion in 2022 to USD 35.9 billion by 2030, registering a CAGR of 13.1% from 2022 to 2030.

article thumbnail

FDA Rejects Lilly’s Eczema Treatment Over Third-Party Manufacturing Issues

BioSpace

Eli Lilly’s Biologic License Application for its monoclonal antibody lebrikizumab was denied by the regulator after issues were found at a third-party contract manufacturing organization.

article thumbnail

CMO Moves: Regulatory Catalysts for Drug Manufacturing-November

Pharmaceutical Technology

However, efficiently manufacturing the drug represents another barrier to cross before realizing the full revenue potential then successfully. Each month, Pharmaceutical Technology takes a look at recent decisions taken by regulatory and reimbursement agencies and identifies the key manufacturing players that can be impacted by them.

article thumbnail

ADC (Antibody Drug Conjugates) Contract Manufacturing Market, 2030 – ResearchAndMarkets.com

BioTech 365

ADC (Antibody Drug Conjugates) Contract Manufacturing Market, 2030 – ResearchAndMarkets.com ADC (Antibody Drug Conjugates) Contract Manufacturing Market, 2030 – ResearchAndMarkets.com DUBLIN–(BUSINESS WIRE)–The “ADC Contract Manufacturing Market (4th Edition) by Phase of Development, Type of Component Manufacturing, Target (..)

article thumbnail

Covid-19 Omicron boosters will reinvigorate injectables manufacturing

Pharmaceutical Technology

Pfizer (New York, New York) and Moderna’s (Cambridge, Massachusetts) Omicron-specific Covid-19 vaccines are in late-stage development, have demonstrated good efficacy against the variant and will likely be available to the public later this year to provide an additional booster and increase demand for injectable manufacturing.